pemetrexed + cisplatin
Phase 1/2Terminated 0 watching 0 views this week⚡ Active
41
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Small Cell Lung Cancer
Conditions
Small Cell Lung Cancer, Carcinoma, Small Cell, SCLC
Trial Timeline
Feb 1, 2007 → May 1, 2008
NCT ID
NCT00447421About pemetrexed + cisplatin
pemetrexed + cisplatin is a phase 1/2 stage product being developed by Eli Lilly for Small Cell Lung Cancer. The current trial status is terminated. This product is registered under clinical trial identifier NCT00447421. Target conditions include Small Cell Lung Cancer, Carcinoma, Small Cell, SCLC.
Hype Score Breakdown
Clinical
13
Activity
8
Company
10
Novelty
4
Community
3
Clinical Trials (15)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00040625 | Pre-clinical | Completed |
| NCT01000480 | Phase 2 | Completed |
| NCT00887549 | Phase 2 | Completed |
| NCT00895648 | Phase 2 | Terminated |
| NCT00475657 | Phase 2 | Terminated |
| NCT00447421 | Phase 1/2 | Terminated |
| NCT00415168 | Phase 2 | Completed |
| NCT00386815 | Phase 2 | Completed |
| NCT00374868 | Phase 1/2 | Completed |
| NCT00259285 | Phase 2 | Terminated |
| NCT00251550 | Phase 1/2 | Completed |
| NCT00191308 | Phase 2 | Completed |
| NCT00320515 | Phase 1/2 | Completed |
| NCT00190801 | Phase 2 | Completed |
| NCT00087698 | Phase 2 | Completed |
Competing Products
20 competing products in Small Cell Lung Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| BBP-398 with nivolumab | BridgeBio Pharma | Phase 1 | 30 |
| Pemetrexed + Carboplatin | Eli Lilly | Phase 3 | 77 |
| Necitumumab + Gemcitabine + Carboplatin | Eli Lilly | Phase 2 | 52 |
| Selpercatinib | Eli Lilly | Pre-clinical | 23 |
| Pemetrexed + Cisplatin + Placebo + Pemetrexed | Eli Lilly | Phase 3 | 77 |
| NBTXR3 | Nanobiotix | Phase 1/2 | 36 |
| Pemetrexed | Eli Lilly | Pre-clinical | 23 |
| pemetrexed + erlotinib | Eli Lilly | Phase 2 | 52 |
| LY3295668 Erbumine | Eli Lilly | Phase 1 | 33 |
| FYB206 + FYB206 + Keytruda | Formycon AG | Phase 3 | 69 |
| 6-Thio-2'-Deoxyguanosine + Cemiplimab | MAIA Biotechnology | Phase 2 | 44 |
| 6-Thio-2'-Deoxyguanosine + Cemiplimab + Docetaxel + Vinorelbine + Gemcitabine alone | MAIA Biotechnology | Phase 3 | 69 |
| pemetrexed + cisplatin | Eli Lilly | Phase 2 | 52 |
| gemcitabine + carboplatin + cisplatin | Eli Lilly | Phase 2 | 52 |
| Cetuximab | Eli Lilly | Phase 1 | 33 |
| pemetrexed + docetaxel | Eli Lilly | Phase 3 | 77 |
| enzastaurin + pemetrexed + docetaxel + carboplatin | Eli Lilly | Phase 2 | 52 |
| PemCarbo + Pem only | Eli Lilly | Phase 3 | 77 |
| TNG456 + abemaciclib | Eli Lilly | Phase 1/2 | 41 |
| LY2875358 + Erlotinib | Eli Lilly | Phase 2 | 52 |